Darusentan Decent, But Can Cardio Fix Gilead's Patent Cliff?
By Trista Morrison
Monday, April 13, 2009
Gilead Sciences Inc.'s push to diversify away from HIV and into cardiovascular disease kicked into high gear with the proposed $1.4 billion acquisition of CV Therapeutics Inc. and positive data from a Phase III trial of Gilead's own resistant hypertension drug, darusentan.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.